U.K.-based CDMO Upperton Pharma Solutions expanded its production footprint with the completion of a new £7 million ($8.1 million) sterile manufacturing facility at its Nottingham campus.
Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end report that it's in a stronger position going into 2025 thanks to improved ...